About
Drugs targeting disorders caused by nucleotide-repeat expansions
Areas of Focus
Categories
Small Molecule PharmaceuticalSan Diego & Southern California
Team (16)
Aseem Ansari
Design Therapeutics
team_member
Chengzhi Zhang
Chengzhi Zhang, Ph.D.Chief Chemist
Design Therapeutics
team_member
Chris Storgard
Chris Storgard, M.D.Chief Medical Officer
Design Therapeutics
executive
Deepa Prasad
Design Therapeutics
team_member
Doane Chilcoat
Doane Chilcoat, Ph.D.Chief Technology Officer
Design Therapeutics
executive
Heather Berger
Design Therapeutics
team_member
Clinical Trials (5)
View allTotal Trials
5
As Lead Sponsor
5
As Collaborator
0
Total Enrollment
155
By Phase
PHASE2: 1PHASE1/PHASE2: 1PHASE1: 3
By Status
RECRUITING: 2COMPLETED: 2NOT_YET_RECRUITING: 1
Clinical Trials Pipeline5 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT07024693Lead Sponsor
DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy
PHASE2Recruiting
28 participants
Started: Jul 31, 2025 · Completed: Dec 31, 2026
NCT06874010Lead Sponsor
A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia
PHASE1/PHASE2Recruiting
20 participants
Started: Jun 30, 2025 · Completed: Mar 31, 2027
NCT06772870Lead Sponsor
A Single Ascending Dose Study of DT-216P2 in Normal Healthy Participants
PHASE1Not yet recruiting
36 participants
Started: Feb 28, 2025 · Completed: Dec 31, 2025
NCT05573698Lead Sponsor
Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich Ataxia
PHASE1Completed
32 participants
Started: Sep 27, 2022 · Completed: Aug 25, 2023
NCT05285540Lead Sponsor
Study to Evaluate DT-216 in Adult Patients With Friedreich Ataxia
PHASE1Completed
39 participants
Started: Mar 11, 2022 · Completed: Dec 19, 2022
Locations (1)
Headquarters
Carlsbad, CA, United States
Map
Loading map...